Stock NXTC NEXTCURE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials NextCure, Inc.

Equities

NXTC

US65343E1082

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.35 USD +4.65% Intraday chart for NextCure, Inc. -15.62% +18.42%
Apr. 08 NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024 CI
Apr. 04 NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,546 300.3 165.8 39.16 31.81 37.76 - -
Enterprise Value (EV) 1 1,216 20.35 165.8 39.16 31.81 37.76 37.76 37.76
P/E ratio -26.2 x -8.2 x -2.39 x -0.52 x -0.51 x -0.81 x -0.8 x -1.41 x
Yield - - - - - - - -
Capitalization / Revenue 244 x 13.4 x - - - - - -
EV / Revenue 244 x 13.4 x - - - - - -
EV / EBITDA -44,428,598 x -7,942,674 x -2,607,519 x -545,547 x - - - -
EV / FCF -39.6 x - -2.78 x - - -0.79 x -0.6 x -0.52 x
FCF Yield -2.52% - -36% - - -127% -167% -193%
Price to Book 2.75 x 1.02 x - - - - - -
Nbr of stocks (in thousands) 27,443 27,553 27,626 27,775 27,903 27,973 - -
Reference price 2 56.33 10.90 6.000 1.410 1.140 1.350 1.350 1.350
Announcement Date 3/12/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 6.347 22.38 - - - - - -
EBITDA -34.79 -37.81 -63.57 -71.78 - - - -
EBIT 1 -37.48 -41.22 -70.76 -75.91 -67.64 -50.14 -52.43 -61.42
Operating Margin -590.55% -184.22% - - - - - -
Earnings before Tax (EBT) 1 -33.74 -36.6 -69.39 -74.73 -62.72 -46.16 -49.34 -58.33
Net income 1 -33.74 -36.6 -69.39 -74.73 -62.72 -46.89 -50.38 -58.33
Net margin -531.54% -163.57% - - - - - -
EPS 2 -2.150 -1.330 -2.510 -2.690 -2.250 -1.670 -1.685 -0.9600
Free Cash Flow 1 -38.99 - -59.6 - - -48 -63 -73
FCF margin -614.37% - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/12/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -18.51 -17.07 -20.77 -18.13 -19.24 -17.77 -17.07 -19.16 -15.62 -15.79 -13.78 -12.46 -11.84 -12.06 -11.88
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -17.93 -16.94 -20.6 -17.92 -18.91 -17.3 -16.1 -17.86 -14.3 -14.47 -13.12 -11.44 -10.64 -10.95 -9.7
Net income 1 -17.93 -16.94 -20.6 -17.92 -18.91 -17.3 -16.1 -17.86 -14.3 -14.47 -12.84 -11.6 -11.1 -11.35 -11.48
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.6500 -0.6100 -0.7400 -0.6500 -0.6800 -0.6200 -0.5800 -0.6400 -0.5100 -0.5200 -0.4600 -0.4125 -0.3950 -0.4000 -0.4050
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 3/3/22 5/5/22 8/4/22 11/3/22 3/2/23 5/4/23 8/3/23 11/2/23 3/21/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position 330 280 - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -39 - -59.6 - - -48 -63 -73
ROE (net income / shareholders' equity) -24.6% -11.9% -26.3% -37.3% - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 20.50 10.70 - - - - - -
Cash Flow per Share -2.270 -1.630 -2.070 -1.940 - - - -
Capex 1 3.37 7.13 2.36 - - 1 1 1
Capex / Sales 53.11% 31.87% - - - - - -
Announcement Date 3/12/20 3/4/21 3/3/22 3/2/23 3/21/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.35 USD
Average target price
5 USD
Spread / Average Target
+270.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
NEXTCURE, INC. Stock NextCure, Inc.
+18.42% 37.76M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. NXTC Stock
  4. Financials NextCure, Inc.